Paysign reports record Q2 revenue $28.3M (+48%), raises FY2026 outlook

Paysign, Inc.

Revenue $28.25M, up 48.1% YoY; GAAP net income $6.76M ($0.11 EPS) vs $1.39M ($0.02) prior year.
Pharma revenue $14.65M (+88.9%) with 148 active programs; plasma revenue $13.04M (+21.4%) with 561 centers.
Adjusted EBITDA $9.61M, up 113%; operating margin 24.8% (21.3% ex contingent consideration).
Raised FY2026 revenue guidance to $114-117M and adjusted EBITDA to $35-38M.
Balance sheet: $27.37M unrestricted cash, zero bank debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.